Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00729690 · ClinicalTrials.gov registry record · Phase 3
Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement
A Phase 3 study, sponsored by Asokumar Buvanendran.
- Completed
- Registry status
- Phase 3
- Development phase
- 48
- Enrollment target
NCT00729690 is a Phase 3 study that has completed, run by Asokumar Buvanendran. The registered enrollment target is 48 participants.
The verdict
NCT00729690, a Phase 3 study, has completed, sponsored by Asokumar Buvanendran.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 48 participants
- Enrollment target
Study Summary
This study involves research. Pregabalin is a Food and Drug Administration (FDA) medication approved in the United States for the treatment of nerve pain related to diabetes and post-herpetic neuralgia "shingles", and for seizures in adults. The purpose of this research is to study the effect of oral Pregabalin on spinal neurotransmitters in subjects undergoing Total Knee Replacement Surgery (TKA). TKA is associated with considerable postoperative pain which if unrelieved may result in prolonged hospital stay, inability to participate in rehabilitation programs, poor outcomes, and greater use of health-care resources. This study examines the effect of pregabalin administered for TKA on pain-related neurotransmitter concentrations.
Interventions
- DRUG Placebo
- DRUG Pregabalin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2008-08 |
| Est. Completion | 2011-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00729690
The ClinicalTrials.gov registry entry for NCT00729690 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Asokumar Buvanendran, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00729690 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00729690 about?
NCT00729690 is a clinical study titled "Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement". This study involves research. Pregabalin is a Food and Drug Administration (FDA) medication approved in the United States for the treatment of nerve pain related to diabetes and post-herpetic neuralgia "shingles", and for seizures in adults. The purpose of this research is to study the effect of ora...
What is the current status of trial NCT00729690?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 48 participants. The study started on 2008-08. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00729690?
The interventions under investigation include: Placebo (DRUG), Pregabalin (DRUG).
Who is sponsoring clinical trial NCT00729690?
This trial is sponsored by Asokumar Buvanendran, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.